var data={"title":"Determinants of glucocorticoid dosing","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Determinants of glucocorticoid dosing</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/contributors\" class=\"contributor contributor_credentials\">Daniel E Furst, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/contributors\" class=\"contributor contributor_credentials\">Kenneth G Saag, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/contributors\" class=\"contributor contributor_credentials\">Eric L Matteson, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/contributors\" class=\"contributor contributor_credentials\">Monica Ramirez Curtis, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 27, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Natural and synthetic glucocorticoids (also called steroids) can be used for a variety of disorders. These agents are most commonly given in pharmacologic doses to manage conditions that require the suppression of inflammation. Less often, they are used to establish the diagnosis and cause of Cushing's syndrome and for hormone replacement in adrenal insufficiency and congenital adrenal hyperplasia.</p><p>The determinants of glucocorticoid dosing include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pharmacokinetics of the different drug preparations</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Effects of underlying disorders on drug kinetics</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Interactions of glucocorticoids with concurrently administered non-glucocorticoid drugs</p><p/><p>This topic will review the factors that affect glucocorticoid dosing. A detailed discussion of the structure, absorption, metabolism, and biologic activities of glucocorticoids is presented separately. (See <a href=\"topic.htm?path=pharmacologic-use-of-glucocorticoids\" class=\"medical medical_review\">&quot;Pharmacologic use of glucocorticoids&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">BIOEQUIVALENCE AND BIOAVAILABILITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The different preparations of glucocorticoids are largely bioequivalent (ie, have the same rate of absorption). As an example, most commercially available <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> tablets are bioequivalent, independent of tablet strength (eg, 1, 2, 5, 10, 20 mg) [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/1\" class=\"abstract_t\">1</a>], and the systemic bioavailability of prednisone and <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> are similar. Although the rectal and oral absorption of <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> are variable (relative bioavailability of 50 to 90 percent), such preparations are also bioequivalent [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/2,3\" class=\"abstract_t\">2,3</a>]. Glucocorticoid bioavailability does not appear to be affected, although preeclampsia and gestational hypertension may increase cortisol metabolism (without affecting neonatal birth weight) [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Different formulations of glucocorticoid preparations are being developed to improve delivery of these drugs (eg, palmitate large porous particles, oral dissolvable film formulations, nanosuspensions in soft contact lenses, multidose dry powder inhalers), which may improve the usefulness of glucocorticoids [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/5-8\" class=\"abstract_t\">5-8</a>].</p><p>Incomplete bioavailability of glucocorticoids has occasionally been noted in certain patients. As an example, in one study 20 percent of patients given <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> showed poor bioavailability (23 to 65 percent), compared to only 1 of 12 patients given <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/9\" class=\"abstract_t\">9</a>].</p><p>The dosing equivalents, relative antiinflammatory and mineralocorticoid activity, and duration of action of the different glucocorticoid preparations, shown in the table (<a href=\"image.htm?imageKey=ENDO%2F64138\" class=\"graphic graphic_table graphicRef64138 \">table 1</a>), are discussed separately. (See <a href=\"topic.htm?path=pharmacologic-use-of-glucocorticoids\" class=\"medical medical_review\">&quot;Pharmacologic use of glucocorticoids&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Inhaled glucocorticoids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The bioavailability of inhaled glucocorticoids varies with the physical properties of the particular agent. Eighty percent of inhaled glucocorticoids are swallowed, with the remainder deposited in the lungs. When deposited in the lungs, the more lipophilic compounds (such as <a href=\"topic.htm?path=fluticasone-drug-information\" class=\"drug drug_general\">fluticasone</a> and <a href=\"topic.htm?path=beclomethasone-drug-information\" class=\"drug drug_general\">beclomethasone</a>) are retained longer in lung tissue.</p><p>The absorption of inhaled glucocorticoids also varies with the specific agents. Drugs that are highly lipophilic are relatively poorly absorbed orally (less than 11 percent). By comparison, agents which are not lipophilic (such as <a href=\"topic.htm?path=budesonide-drug-information\" class=\"drug drug_general\">budesonide</a>) are somewhat better absorbed orally (less than 20 percent). Since all of the drug deposited in the lung eventually enters the systemic circulation, overall absorption of inhaled glucocorticoids varies between 20 and 40 percent of the administered dose [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">DISPOSITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">Prednisone</a> is rapidly metabolized via reduction to <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a>; the elimination of prednisone is approximately 13 times faster than prednisolone [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/11\" class=\"abstract_t\">11</a>]. In contrast to cortisol, the endogenously produced glucocorticoid, the synthetic glucocorticoids bind less or minimally to cortisol-binding globulin (CBG, transcortin). Prednisolone has about 60 percent, prednisone 5 percent, and <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a>, <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, <a href=\"topic.htm?path=betamethasone-drug-information\" class=\"drug drug_general\">betamethasone</a>, and <a href=\"topic.htm?path=triamcinolone-drug-information\" class=\"drug drug_general\">triamcinolone</a> have less than 1 percent of the affinity of cortisol for CBG. (See <a href=\"topic.htm?path=pharmacologic-use-of-glucocorticoids\" class=\"medical medical_review\">&quot;Pharmacologic use of glucocorticoids&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Clearance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clearance of <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> is 210 <span class=\"nowrap\">mL/min</span> per 1.73 m<sup>2</sup>, with an elimination half-life of approximately three hours. Clearance decreases with age; as an example, children less than 12 years of age have a 33 percent higher clearance than older children and adults [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Glucocorticoids exhibit dose-dependent kinetics. Total <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> clearance increases by 75 percent as the intravenous dose increases from 5 to 40 mg [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/12,13\" class=\"abstract_t\">12,13</a>]. Free prednisolone clearances also change with administered dose, but to a lesser degree and require larger doses to demonstrate such kinetics [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/14\" class=\"abstract_t\">14</a>]. The clinical consequence of these properties is that a somewhat greater, nonlinear drug effect is observed at prednisolone doses over 40 mg compared to doses between 10 to 20 mg.</p><p>Clearances also vary with the time of day. Both <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> and <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> clearance is lower (18 to 28 percent) in the morning than the evening [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/15,16\" class=\"abstract_t\">15,16</a>]. This property, in combination with the disruption of the usual cortisol diurnal rhythm with exogenous glucocorticoids, may result in variations in efficacy when glucocorticoids are administered at different times during the day [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/17,18\" class=\"abstract_t\">17,18</a>]. In one study, for example, the efficacy of prednisolone was assessed in seven asthmatic patients in whom the drug was given at 8 AM and 3 PM, and at 3 PM and 8 PM [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/19\" class=\"abstract_t\">19</a>]. The earlier dosing regimen was more effective in improving nocturnal pulmonary function and symptoms.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Distribution in breast milk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Glucocorticoids are excreted in small amounts in human milk. In one study, approximately 0.23 percent of a 5 mg <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> dose was found in breast milk [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/20\" class=\"abstract_t\">20</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">DISEASES AND ALTERED PHYSIOLOGIC STATES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pharmacokinetics of glucocorticoids vary with certain diseases and pathophysiologic conditions.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Asthma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no clinically important pharmacokinetic differences between asthmatic patients and healthy subjects [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Cystic fibrosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The bioavailability of <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> appears to be unaffected by cystic fibrosis, but the total prednisolone clearance was increased by over 50 percent [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/22\" class=\"abstract_t\">22</a>]. As a result, more frequent dosing may be necessary.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">End-stage renal disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among patients treated with hemodialysis, the clearance of total <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> is dose-dependent, while the clearance of unbound prednisolone is constant [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/23\" class=\"abstract_t\">23</a>]. Hemodialysis also removes significant amounts of <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a>, thereby resulting in a 32 percent reduction in plasma half-life relative to normals [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/24\" class=\"abstract_t\">24</a>]. However, these changes are not sufficient to require a dose adjustment. The removal rate of unbound cortisol in patients treated with peritoneal dialysis is similar to normal individuals [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/24,25\" class=\"abstract_t\">24,25</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Hyperthyroidism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clearance of <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> is increased in hyperthyroidism. In one small study, total prednisolone clearance was increased by 58 percent and nonrenal clearance (principally hepatic) was increased by 84 percent [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/26\" class=\"abstract_t\">26</a>]. There were also small changes in absorption and binding.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Inflammatory bowel disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The overall kinetics of <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> do not appear to be affected by inflammatory bowel disease (IBD). One study, for example, found that total and unbound kinetics of prednisolone were unchanged in active and inactive IBD, although the unbound fraction was increased in active disease [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Nephrotic syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients have low serum concentrations of albumin and cortisol-binding globulin. However, although their bound and therefore total glucocorticoid concentrations are reduced, the physiologically important unbound (free) serum concentrations of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> and <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> are similar to nonnephrotic individuals.</p><p>Perhaps because of the differences in protein-binding, nonrenal clearance is higher and renal clearance is lower in patients with the nephrotic syndrome than in normal individuals [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/28\" class=\"abstract_t\">28</a>]. The total <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> clearances are higher in nephrotic patients, since the increase in nonrenal clearance is of greater magnitude than the reduction in renal clearance.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Obesity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Obesity can affect the uptake, storage, and metabolism of glucocorticoids, although results are somewhat contradictory.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one study, the volume of distribution and clearance of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> in obese men weighing more than 133 percent of ideal body weight was 20 to 30 percent higher than in normal weight controls [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/29\" class=\"abstract_t\">29</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another report indicated that each 1 percent higher baseline body mass index (BMI) was associated with a 2.9 percent decline in wake-up and total area under curve (AUC) cortisol, suggesting that a higher BMI suppresses cortisol [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/30\" class=\"abstract_t\">30</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>By contrast, two other reports that examined the metabolism of <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> and <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> found that clearance among obese patients was decreased by about 40 percent when compared to normals [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/31,32\" class=\"abstract_t\">31,32</a>]. One of these studies also examined pharmacodynamic measures of glucocorticoid activity, particularly histamine and T cell responses [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/31\" class=\"abstract_t\">31</a>]. Although not statistically significant, there was a clear trend toward an enhanced effect in obese subjects at the same <span class=\"nowrap\">mg/kg</span> dose.</p><p/><p>Dosing of glucocorticoids in the obese patient should be based upon the ideal, rather than total, body weight.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Little active <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> crosses the placenta to the fetus, since the placenta inactivates the drug. However, <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> clearance is increased approximately twofold when compared to nonpregnant women, probably due to enzyme induction [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/33\" class=\"abstract_t\">33</a>].</p><p>When an effect on the fetus is desired, for example to speed fetal lung maturity in situations where premature delivery is anticipated, fluorinated glucocorticoids are used because these cross the placenta and have pharmacologic effects on the fetal organs. <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">Dexamethasone</a> and <a href=\"topic.htm?path=betamethasone-drug-information\" class=\"drug drug_general\">betamethasone</a> are often used in this setting. Use of antenatal betamethasone is associated with a lower risk of neonatal death than is dexamethasone [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/34\" class=\"abstract_t\">34</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Severe liver disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the presence of severe liver disease, the activation of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> via metabolism to 6-beta-hydroxyl compounds may be impaired, potentially affecting the efficacy of glucocorticoid therapy [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/35\" class=\"abstract_t\">35</a>]. (See <a href=\"topic.htm?path=pharmacologic-use-of-glucocorticoids\" class=\"medical medical_review\">&quot;Pharmacologic use of glucocorticoids&quot;</a>.)</p><p>Patients who undergo liver transplantation because of hepatic C viral infection should receive the lowest dose of glucocorticoids following transplantation that is feasible. The cumulative glucocorticoid dose is correlated closely with post-transplantation hepatitis-C viral load and with mortality rates [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/36\" class=\"abstract_t\">36</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">DRUG INTERACTIONS</span></p><p class=\"headingAnchor\" id=\"H11170647\"><span class=\"h2\">Systemic glucocorticoids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Glucocorticoids undergo metabolism in the liver and other tissues by cytochrome P450 3A4 (CYP 3A4) and other transformations. In vitro data suggest that <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> and <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> are also substrates of P-glycoprotein membrane efflux transporters. Medications that strongly inhibit or induce CYP 3A4 <span class=\"nowrap\">and/or</span> P-glycoprotein transporters may significantly alter the glucocorticoid serum concentration [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/37,38\" class=\"abstract_t\">37,38</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medications that increase the systemic glucocorticoid concentration include estrogen derivatives, such as oral contraceptives [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/39-42\" class=\"abstract_t\">39-42</a>] and strong inhibitors of CYP 3A4 (<a href=\"image.htm?imageKey=CARD%2F76992\" class=\"graphic graphic_table graphicRef76992 \">table 2</a>) including some antibiotics (eg, <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>, <a href=\"topic.htm?path=ritonavir-drug-information\" class=\"drug drug_general\">ritonavir</a>, <a href=\"topic.htm?path=telaprevir-united-states-not-available-drug-information\" class=\"drug drug_general\">telaprevir</a>, <a href=\"topic.htm?path=telithromycin-drug-information\" class=\"drug drug_general\">telithromycin</a>) [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/43-45\" class=\"abstract_t\">43-45</a>], and antifungals (eg, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>) [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/38,46,47\" class=\"abstract_t\">38,46,47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medications that reduce the systemic glucocorticoid concentration include <span class=\"nowrap\">aluminum/magnesium</span> containing antacids, which decrease <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> bioavailability due to decreased oral absorption [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/48,49\" class=\"abstract_t\">48,49</a>], and strong inducers of CYP 3A4 (eg, <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a>, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>) [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/50-55\" class=\"abstract_t\">50-55</a>].</p><p/><p>However, a number of agents often used with glucocorticoids appear to have no substantial interaction with them. These include <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, histamine<sub>2 </sub>antagonists (eg, <a href=\"topic.htm?path=famotidine-drug-information\" class=\"drug drug_general\">famotidine</a>, <a href=\"topic.htm?path=cimetidine-drug-information\" class=\"drug drug_general\">cimetidine</a>, <a href=\"topic.htm?path=ranitidine-drug-information\" class=\"drug drug_general\">ranitidine</a>), proton pump inhibitors (eg, <a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">omeprazole</a>, <a href=\"topic.htm?path=pantoprazole-drug-information\" class=\"drug drug_general\">pantoprazole</a>, <a href=\"topic.htm?path=rabeprazole-drug-information\" class=\"drug drug_general\">rabeprazole</a>), and <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a> [<a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/50,56-60\" class=\"abstract_t\">50,56-60</a>].</p><p>The major drug interactions with systemic glucocorticoids, a summary of effect(s), and management suggestions are listed in the table (<a href=\"image.htm?imageKey=RHEUM%2F53228\" class=\"graphic graphic_table graphicRef53228 \">table 3</a>). For additional interactions, see Lexi-Interact, the drug interactions program included with UpToDate.</p><p class=\"headingAnchor\" id=\"H11170962\"><span class=\"h2\">Inhaled or intranasal glucocorticoids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Inhibitors of CYP 3A4 may impair the metabolism of glucocorticoids administered intranasally or by inhalation and may increase the serum concentration associated with these methods of administration. Use caution when combining high-dose intranasal or inhaled glucocorticoids with strong CYP 3A4 inhibitors (<a href=\"image.htm?imageKey=CARD%2F76992\" class=\"graphic graphic_table graphicRef76992 \">table 2</a>). This is discussed elsewhere. (See <a href=\"topic.htm?path=pharmacotherapy-of-allergic-rhinitis#H2446146\" class=\"medical medical_review\">&quot;Pharmacotherapy of allergic rhinitis&quot;, section on 'Possible drug interactions'</a> and <a href=\"topic.htm?path=major-side-effects-of-inhaled-glucocorticoids#H26\" class=\"medical medical_review\">&quot;Major side effects of inhaled glucocorticoids&quot;, section on 'Medication interactions'</a>.)</p><p class=\"headingAnchor\" id=\"H198637278\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The determinants of glucocorticoid dosing include pharmacokinetics of the different drug preparations, effects of underlying disorders on drug kinetics, and interactions of glucocorticoids with concurrently administered non-glucocorticoid drugs. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The different preparations of glucocorticoids are largely bioequivalent (ie, have the same rate of absorption). The systemic bioavailability of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> and <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> are similar; the rectal and oral absorption of <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> are variable (relative bioavailability of 50 to 90 percent). Incomplete bioavailability of glucocorticoids has occasionally been noted. The bioavailability of inhaled glucocorticoids varies with the physical properties of the particular agent. (See <a href=\"#H2\" class=\"local\">'Bioequivalence and bioavailability'</a> above and <a href=\"#H3\" class=\"local\">'Inhaled glucocorticoids'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The dosing equivalents, relative antiinflammatory and mineralocorticoid activity, and duration of action of the different glucocorticoid preparations, shown in the table (<a href=\"image.htm?imageKey=ENDO%2F64138\" class=\"graphic graphic_table graphicRef64138 \">table 1</a>), are discussed separately. (See <a href=\"topic.htm?path=pharmacologic-use-of-glucocorticoids\" class=\"medical medical_review\">&quot;Pharmacologic use of glucocorticoids&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">Prednisone</a> is rapidly metabolized via reduction to <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a>. In contrast to cortisol, the endogenously-produced glucocorticoid, the synthetic glucocorticoids bind less or minimally to cortisol-binding globulin. Prednisolone has an elimination half-life of approximately three hours; clearance decreases with age and varies with time of day. Kinetics are dose-dependent. Only small amounts are excreted in breast milk. (See <a href=\"#H4\" class=\"local\">'Disposition'</a> above and <a href=\"#H5\" class=\"local\">'Clearance'</a> above and <a href=\"#H6\" class=\"local\">'Distribution in breast milk'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The pharmacokinetics of glucocorticoids vary with certain diseases and pathophysiologic conditions, including cystic fibrosis, end-stage renal disease and hemodialysis, hyperthyroidism, nephrotic syndrome, obesity, pregnancy, and severe liver disease. (See <a href=\"#H7\" class=\"local\">'Diseases and altered physiologic states'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Significant interactions with glucocorticoids have been documented for the medications listed in the table (<a href=\"image.htm?imageKey=RHEUM%2F53228\" class=\"graphic graphic_table graphicRef53228 \">table 3</a>); a change of less than 30 percent is not likely to be clinically significant. Agents often used with glucocorticoids that appear to have no substantial interaction with them include <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, <a href=\"topic.htm?path=cimetidine-drug-information\" class=\"drug drug_general\">cimetidine</a>, <a href=\"topic.htm?path=ranitidine-drug-information\" class=\"drug drug_general\">ranitidine</a>, <a href=\"topic.htm?path=theophylline-drug-information\" class=\"drug drug_general\">theophylline</a>, and <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a>. (See <a href=\"#H17\" class=\"local\">'Drug interactions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drugs that reduce the systemic glucocorticoid concentration include large doses of <span class=\"nowrap\">aluminum/<a href=\"topic.htm?path=magnesium-hydroxide-drug-information\" class=\"drug drug_general\">magnesium hydroxide</a>,</span> which decrease bioavailability, and most anticonvulsants, which enhance glucocorticoid metabolism. Drugs that raise the systemic glucocorticoid concentration include some oral contraceptives, and certain antibiotics and antifungal agents; these drugs decrease metabolizing enzymes. (See <a href=\"#H17\" class=\"local\">'Drug interactions'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/1\" class=\"nounderline abstract_t\">Francisco GE, Honigberg IL, Stewart JT, et al. In vitro and in vivo bioequivalence of commercial prednisone tablets. Biopharm Drug Dispos 1984; 5:335.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/2\" class=\"nounderline abstract_t\">Lima JJ, Giller J, Mackichan JJ, Jusko WJ. Bioavailability of hydrocortisone retention enemas in normal subjects. Am J Gastroenterol 1980; 73:232.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/3\" class=\"nounderline abstract_t\">Garg DC, Wagner JG, Sakmar E, et al. Rectal and oral absorption of methylprednisolone acetate. Clin Pharmacol Ther 1979; 26:232.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/4\" class=\"nounderline abstract_t\">Kosicka K, Siemi&#261;tkowska A, Krzy&#347;cin M, et al. Glucocorticoid Metabolism in Hypertensive Disorders of Pregnancy: Analysis of Plasma and Urinary Cortisol and Cortisone. PLoS One 2015; 10:e0144343.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/5\" class=\"nounderline abstract_t\">N'Guessan A, Fattal E, Chapron D, et al. Dexamethasone palmitate large porous particles: A controlled release formulation for lung delivery of corticosteroids. Eur J Pharm Sci 2018; 113:185.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/6\" class=\"nounderline abstract_t\">Diamant Z, Samuelsson Palmgren G, Westrin B, Bjermer L. Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets. Eur Clin Respir J 2017; 4:1353395.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/7\" class=\"nounderline abstract_t\">Garc&iacute;a-Mill&aacute;n E, Quint&aacute;ns-Carballo M, Otero-Espinar FJ. Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug nanosuspensions. Int J Pharm 2017; 525:226.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/8\" class=\"nounderline abstract_t\">Bernstein DI, Gillespie M, Song S, Steinfeld J. Safety, efficacy, and dose response of fluticasone propionate delivered via the novel MDPI in patients with severe asthma: A randomized, controlled, dose-ranging study. J Asthma 2017; 54:559.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/9\" class=\"nounderline abstract_t\">Hill MR, Szefler SJ, Ball BD, et al. Monitoring glucocorticoid therapy: a pharmacokinetic approach. Clin Pharmacol Ther 1990; 48:390.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/10\" class=\"nounderline abstract_t\">Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996; 97:169.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/11\" class=\"nounderline abstract_t\">Hale VG, Aizawa K, Sheiner LB, Benet LZ. Disposition of prednisone and prednisolone in the perfused rabbit liver: modeling hepatic metabolic processes. J Pharmacokinet Biopharm 1991; 19:597.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/12\" class=\"nounderline abstract_t\">Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 1981; 9:389.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/13\" class=\"nounderline abstract_t\">Legler UF, Frey FJ, Benet LZ. Prednisolone clearance at steady state in man. J Clin Endocrinol Metab 1982; 55:762.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/14\" class=\"nounderline abstract_t\">Wald JA, Law RM, Ludwig EA, et al. Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. J Pharmacokinet Biopharm 1992; 20:567.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/15\" class=\"nounderline abstract_t\">Meffin PJ, Wing LM, Sallustio BC, Brooks PM. Alterations in prednisolone disposition as a result of oral contraceptive use and dose. Br J Clin Pharmacol 1984; 17:655.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/16\" class=\"nounderline abstract_t\">Fisher LE, Ludwig EA, Wald JA, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm. Clin Pharmacol Ther 1992; 51:677.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/17\" class=\"nounderline abstract_t\">Sugita ET, Niebergall PJ. Bioavailability monograph: Prednisolone. J Am Pharm Assoc 1975; NS15:529.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/18\" class=\"nounderline abstract_t\">Theissen JJ. Bioavailability monograph: Prednisolone. J Am Pharm Assoc 1976; NS16:143.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/19\" class=\"nounderline abstract_t\">Reinberg A, Gervais P, Chaussade M, et al. Circadian changes in effectiveness of corticosteroids in eight patients with allergic asthma. J Allergy Clin Immunol 1983; 71:425.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/20\" class=\"nounderline abstract_t\">Brooks PM, Needs CJ. The use of antirheumatic medication during pregnancy and in the puerperium. Rheum Dis Clin North Am 1989; 15:789.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/21\" class=\"nounderline abstract_t\">Mortimer O, Grettve L, Lindstr&ouml;m B, et al. Bioavailability of prednisolone in asthmatic patients with a poor response to steroid treatment. Eur J Respir Dis 1987; 71:372.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/22\" class=\"nounderline abstract_t\">Dove AM, Szefler SJ, Hill MR, et al. Altered prednisolone pharmacokinetics in patients with cystic fibrosis. J Pediatr 1992; 120:789.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/23\" class=\"nounderline abstract_t\">Frey FJ, Gambertoglio JG, Frey BM, et al. Nonlinear plasma protein binding and haemodialysis clearance of prednisolone. Eur J Clin Pharmacol 1982; 23:65.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/24\" class=\"nounderline abstract_t\">Sherlock JE, Letteri JM. Effect of hemodialysis on methylprednisolone plasma levels. Nephron 1977; 18:208.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/25\" class=\"nounderline abstract_t\">Zager PG, Spalding CT, Frey HJ, et al. Dialysance of adrenocorticoids during continuous ambulatory peritoneal dialysis. J Clin Endocrinol Metab 1988; 67:110.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/26\" class=\"nounderline abstract_t\">Frey FJ, Horber FF, Frey BM. Altered metabolism and decreased efficacy of prednisolone and prednisone in patients with hyperthyroidism. Clin Pharmacol Ther 1988; 44:510.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/27\" class=\"nounderline abstract_t\">Milsap RL, George DE, Szefler SJ, et al. Effect of inflammatory bowel disease on absorption and disposition of prednisolone. Dig Dis Sci 1983; 28:161.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/28\" class=\"nounderline abstract_t\">Frey FJ, Frey BM. Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. Am J Kidney Dis 1984; 3:339.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/29\" class=\"nounderline abstract_t\">Milsap RL, Plaisance KI, Jusko WJ. Prednisolone disposition in obese men. Clin Pharmacol Ther 1984; 36:824.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/30\" class=\"nounderline abstract_t\">Joseph JJ, Wang X, Diez Roux AV, et al. Antecedent longitudinal changes in body mass index are associated with diurnal cortisol curve features: The multi-ethnic study of atherosclerosis. Metabolism 2017; 68:95.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/31\" class=\"nounderline abstract_t\">Dunn TE, Ludwig EA, Slaughter RL, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 1991; 49:536.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/32\" class=\"nounderline abstract_t\">Lamiable D, Vistelle R, Sulmont V, et al. [Pharmacokinetics of dexamethasone administered orally in obese patients]. Therapie 1990; 45:311.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/33\" class=\"nounderline abstract_t\">Tsuei SE, Petersen MC, Ashley JJ, et al. Disporition of synthetic glucocorticoids. II. Dexamethasone in parturient women. Clin Pharmacol Ther 1980; 28:88.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/34\" class=\"nounderline abstract_t\">Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol 2004; 190:878.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/35\" class=\"nounderline abstract_t\">Renner E, Horber FF, Jost G, et al. Effect of liver function on the metabolism of prednisone and prednisolone in humans. Gastroenterology 1986; 90:819.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/36\" class=\"nounderline abstract_t\">Charlton M. Management of recurrence of hepatitis C infection following liver transplantation. Minerva Chir 2003; 58:717.</a></li><li class=\"breakAll\">Gary H. Wynn. Transplant surgery and rheumatology. In: Clinical manual of drug interaction principles for medical practice, 1st ed, Gary H. Wynn (Ed), APA Publishing Inc., Washington DC 2009. p.462.</li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/38\" class=\"nounderline abstract_t\">Czock D, Keller F, Rasche FM, H&auml;ussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44:61.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/39\" class=\"nounderline abstract_t\">Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed Pharmacother 1986; 40:301.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/40\" class=\"nounderline abstract_t\">Boekenoogen SJ, Szefler SJ, Jusko WJ. Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab 1983; 56:702.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/41\" class=\"nounderline abstract_t\">Gustavson LE, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 1986; 62:234.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/42\" class=\"nounderline abstract_t\">Frey BM, Schaad HJ, Frey FJ. Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. Eur J Clin Pharmacol 1984; 26:505.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/43\" class=\"nounderline abstract_t\">LaForce CF, Szefler SJ, Miller MF, et al. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol 1983; 72:34.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/44\" class=\"nounderline abstract_t\">Szefler SJ, Brenner M, Jusko WJ, et al. Dose- and time-related effect of troleandomycin on methylprednisolone elimination. Clin Pharmacol Ther 1982; 32:166.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/45\" class=\"nounderline abstract_t\">Szefler SJ, Ellis EF, Brenner M, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. J Allergy Clin Immunol 1982; 69:455.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/46\" class=\"nounderline abstract_t\">Z&uuml;rcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 1989; 45:366.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/47\" class=\"nounderline abstract_t\">Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther 1991; 49:558.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/48\" class=\"nounderline abstract_t\">Tanner AR, Caffin JA, Halliday JW, Powell LW. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Clin Pharmacol 1979; 7:397.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/49\" class=\"nounderline abstract_t\">Uribe M, Casian C, Rojas S, et al. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. Gastroenterology 1981; 80:661.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/50\" class=\"nounderline abstract_t\">Stjernholm MR, Katz FH. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. J Clin Endocrinol Metab 1975; 41:887.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/51\" class=\"nounderline abstract_t\">Frey FJ, Frey BM. Urinary 6 beta-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism. J Lab Clin Med 1983; 101:593.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/52\" class=\"nounderline abstract_t\">Brooks SM, Werk EE, Ackerman SJ, et al. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 1972; 286:1125.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/53\" class=\"nounderline abstract_t\">Frey BM, Frey FJ. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. Eur J Clin Invest 1984; 14:1.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/54\" class=\"nounderline abstract_t\">Evans PJ, Walker RF, Peters JR, et al. Anticonvulsant therapy and cortisol elimination. Br J Clin Pharmacol 1985; 20:129.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/55\" class=\"nounderline abstract_t\">Petereit LB, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther 1977; 22:912.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/56\" class=\"nounderline abstract_t\">Frey FJ, Lozada F, Guentert T, Frey BM. A single dose of azathioprine does not affect the pharmacokinetics of prednisolone following oral prednisone. Eur J Clin Pharmacol 1981; 19:209.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/57\" class=\"nounderline abstract_t\">Frey FJ, Schnetzer A, Horber FF, Frey BM. Evidence that cyclosporine does not affect the metabolism of prednisolone after renal transplantation. Transplantation 1987; 43:494.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/58\" class=\"nounderline abstract_t\">Glynn-Barnhart AM, Erzurum SC, Leff JA, et al. Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. J Allergy Clin Immunol 1991; 88:180.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/59\" class=\"nounderline abstract_t\">Sirgo MA, Rocci ML Jr, Ferguson RK, et al. Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. Clin Pharmacol Ther 1985; 37:534.</a></li><li><a href=\"https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing/abstract/60\" class=\"nounderline abstract_t\">Brooks SM, Sholiton LJ, Werk EE Jr, Altenau P. The effects of ephedrine and theophylline on dexamethasone metabolism in bronchial asthma. J Clin Pharmacol 1977; 17:308.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7976 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H198637278\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">BIOEQUIVALENCE AND BIOAVAILABILITY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Inhaled glucocorticoids</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">DISPOSITION</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Clearance</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Distribution in breast milk</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">DISEASES AND ALTERED PHYSIOLOGIC STATES</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Asthma</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Cystic fibrosis</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">End-stage renal disease</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Hyperthyroidism</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Inflammatory bowel disease</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Nephrotic syndrome</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Obesity</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Pregnancy</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Severe liver disease</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">DRUG INTERACTIONS</a><ul><li><a href=\"#H11170647\" id=\"outline-link-H11170647\">Systemic glucocorticoids</a></li><li><a href=\"#H11170962\" id=\"outline-link-H11170962\">Inhaled or intranasal glucocorticoids</a></li></ul></li><li><a href=\"#H198637278\" id=\"outline-link-H198637278\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"RHEUM/7976|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/64138\" class=\"graphic graphic_table\">- Comparison of representative glucocorticoid preparations</a></li><li><a href=\"image.htm?imageKey=CARD/76992\" class=\"graphic graphic_table\">- Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers</a></li><li><a href=\"image.htm?imageKey=RHEUM/53228\" class=\"graphic graphic_table\">- Corticosteroid drug interact</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-inhaled-glucocorticoids\" class=\"medical medical_review\">Major side effects of inhaled glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacologic-use-of-glucocorticoids\" class=\"medical medical_review\">Pharmacologic use of glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacotherapy-of-allergic-rhinitis\" class=\"medical medical_review\">Pharmacotherapy of allergic rhinitis</a></li></ul></div></div>","javascript":null}